INTRODUCTION
Obesity-related heart disease, the most serious complication of human obesity, generally is attributed to coexisting disorders such as coronary artery disease and hypertension. However, an increasing body of evidence suggests that cardiac dysfunction, arrhythmias, cardiomyopathy, and congestive heart disease could be direct consequences of obesity and leptin resistance, i.e. fatty acid overload of cardiomyocytes and lipid accumulation in the heart (1, 2). Studies performed on humans, using magnetic resonance spectroscopy, indicate that cardiomyocyte fat correlates well with impaired diastolic filling, even in seemingly asymptomatic obese volunteers (2). One of the proposed reasons is that excess fatty acids or/and their metabolites, i.e. ceramides, induce apoptosis of cardiomyocytes, which is a direct cause of lipotoxic cardiomyopathy and heart failure (2, 3). The important role for ceramide-induced apoptosis in obesity-related cardiomyopathies has been shown in many animal models including leptin insensitive ZDF rats (4), leptin-deficient ob/ob mice (5, 6) , and in a mouse model of heart disease induced by cardiomyocyte-specific overexpression of acyl-CoA synthase (7) . Many maneuvers that reduce ectopic deposition of lipids, i.e. exercise, caloric restriction, troglitazone, were shown to significantly improve cardiac function in obesity, which additionally imply that steatosis might be a primary reason for cardiac dysfunction (2, 8).
Stearoyl-CoA desaturase (SCD) is the rate limiting enzyme catalyzing the biosynthesis of monounsaturated fatty acids, and has been shown to be a key regulatory factor of body adiposity (9) . Mice with a targeted disruption in the SCD1 gene have increased energy expenditure, increased insulin sensitivity, and are resistant to diet-induced obesity (10, 11). SCD1 is involved in regulation of ceramide metabolism. Lack of SCD1 reduces the mRNA level and activity of serine palmitoyltransferase (SPT), the rate limiting enzyme of de novo ceramide synthesis.
Reduced SPT activity together with decreased long chain fatty acyl-CoA levels (mainly by guest, on October 14, 2017 www.jlr.org Downloaded from palmitoyl-CoA) leads to reduced ceramide content in oxidative muscles of SCD1-/-mice (12) . SCD1 deficiency also reduces ceramide synthesis in skeletal muscles of ob/ob mice. Moreover, SCD1 is a major target gene of leptin in liver and was found to be specifically repressed during leptin-mediated weight loss, and leptin-deficient ob/ob mice lacking SCD1 showed markedly reduced adiposity, despite higher food intake (13) . In addition, SCD1 deficiency completely corrects the hypometabolic phenotype and hepatic steatosis of leptin deficient ob/ob mice, thus mimicking the effect of leptin treatment (13) .
Three isoforms of SCD are expressed and regulated in a hormone-dependent fashion in the heart (14) , the molecular and metabolic implications of which are practically unknown. Our recent study showed that the lack of SCD1 decreases fatty acid (FA) uptake and oxidation while increasing glucose transport and oxidation in the heart (15) . This shift in cardiac substrate utilization from FA to glucose is caused by up-regulation of insulin signaling, decreased FA availability, and reduced expression of FA oxidation genes in the heart (15) . Also lipogenesis is decreased in the heart of SCD1-/-mice which is accompanied by reduction in intracellular FA and triglyceride (TG) content (15) . We have also shown that the activity of SCD is significantly increased in the heart of leptin-deficient ob/ob mice (14) , characterized by pathologic left ventricular hypertrophy along with elevated triglyceride content and increased myocyte apoptosis (5, 16) . Taken together, these results suggest that SCD might be involved in pathogenesis of lipotoxic cardiomyopathy induced by lack of leptin action.
Therefore, in the present study, we used the ob/ob;SCD1-/-double knockout mouse model to test the hypothesis that loss of SCD1 function could be beneficial in the treatment of lipid-induced heart disease. Here, for the first time, we show that SCD1 deficiency significantly improves systolic and diastolic function of left ventricle in leptin-deficient ob/ob mice. Lack of SCD1 action resulted in decreased neutral lipids and ceramide accumulation in the heart of ob/ob by guest, on October 14, 2017 www.jlr.org Downloaded from the tip of papillary muscles and Doppler studies were recorded on anesthetized mice (50 mg/kg ketamine). The thickness of the posterior and anterior walls of the left ventricle (LV) chamber and the LV chamber diameter during systole and diastole were measured using the leading edgeto-leading edge convention. All parameters were measured over at least three consecutive cardiac cycles. These parameters were used to calculate LV mass and fractional shortening as previously described (19) . Pulse-wave Doppler was used to measure the velocity of blood through the mitral and aortic valves. From these images, heart rate and the time between closure of the mitral valve and the opening of the aortic valve were calculated.
Blood sampling
Mice were sacrificed by cervical dislocation. Blood was collected aseptically by direct cardiac puncture and centrifuged (13,000 g, 5 min, 4 ºC) to collect plasma. Plasma cholesterol, TG, FFA, insulin and glucose levels were measured by using commercial kits (Roche Applied Science, Indianapolis, IN; Linco Research, St. Charles, MI, Wako Chemicals, Richmond,VA and Sigma, St. Louis, MO).
Isolation and analysis of RNA
Total RNA was isolated from hearts of WT, ob/ob and ob/ob;SCD1-/-mice using TRIzol reagent (Invitrogen, Carlsbad, CA) and then treated with DNase. cDNA was prepared by reverse transcription with random hexamer primers and amplified by PCR using gene-specific primers in the presence of SYBR Green (Applied Biosystems, Foster City, CA) on an ABI Prism 7500 Fast Instrument. Relative abundance of SCD1, SCD4, PPARγ, DGAT, GPAT, CD36, FATP-1, by guest, on October 14, 2017 www.jlr.org
Downloaded from
PPARα, CPT1, ACO, LCB1, and LCB2 mRNA was calculated by normalizing to cyclophilin.
Primer sequences are available upon request.
SCD activity assay
Microsomes were isolated from hearts of WT, ob/ob and ob/ob;SCD1-/-mice by differential centrifugation and suspended in a 0. 
Western blot analysis
To measure FAT/CD36 and FATP protein levels, 100 μg of clarified homogenate protein was loaded onto 9% SDS-PAGE. The separated proteins were transferred to nitrocellulose membranes which were blotted using antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).
The proteins were visualized using ECL as described by the manufacturer (Pierce, Rockford, IL) and quantified by densitometry.
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Measurement of lipids
Heart lipids were extracted by the method of Bligh and Dyer (20) and measured as described (12 (21) . The reaction was terminated by addition of 1.5 ml of chloroform-methanol (2:1, vol/vol). The radiolabeled product, 3-ketosphinganine, was separated from radiolabeled serine by phase partitioning. Sphinganine (25 µg) was added as a carrier, followed by the addition of 1 ml of chloroform and 2 ml of 0.5 N NH 4 OH. The chloroform layer was counted in a scintillation counter (Packard 1900).
[ 14 C]palmitic acid incorporation into ceramide
The mice were anesthetized, and 0. lipid bands corresponding to ceramide were scraped off the plates, and the radioactivity was counted in a liquid scintillation counter (Packard 1900).
Caspase-3 and iNOS activities
To measure caspase-3 activity the heart was homogenized in 10 mM HEPES buffer pH 7.5.
Reaction mixture contained 100 mM HEPES pH 7.5, 5 mM DTT, 0.1% Chaps, 10% sucrose, 16 mM caspase 3 substrate Ac-ASP-Glu-Val-Asp-p-aniline and enzyme. The amount of pnitroaniline reversed by caspase-3 activity was quantitated at 37 °C by measuring the optical density at 405 nm (22) . iNOS activity was assayed using Bioxytech 22113 kit (Oxox International Inc., Portland, OR) (23).
Measurement of fatty acid oxidation
Mitochondria were isolated as described by Scaduto (24) . Mitochondrial FA oxidation was measured as described using [ 14 C]palmitoyl-CoA as substrate (25) . Labeled CO 2 was trapped in
RESULTS
Reduced body weight and epididymal fat mass in SCD1 deficient ob/ob mice
The knockdown of SCD1 gene in ob/ob mice caused significant reduction in body weight (Fig.   1A ). Also the epididymal fat pad mass was markedly reduced in ob/ob;SCD1-/-relative to ob/ob mice (24.8% of body weight vs. 50.2%; p<0.05) (Fig. 1B) . Both body and fat mass were significantly higher in ob/ob;SCD1-/-than in wild-type (WT) mice (Fig. 1A, B ). The concentrations of glucose, insulin, FFA, TG, and cholesterol in plasma were significantly increased in ob/ob mice relative to WT mice (Table 1 ). SCD1 deficiency decreased plasma cholesterol level in ob/ob mice, however concentrations of plasma glucose, insulin, FFA, and TG
were not significantly different between ob/ob;SCD1-/-and ob/ob mice ( Table 1) .
SCD1 deficiency improves cardiac function of ob/ob mice
Transthoracic echocardiography with Doppler flow analysis was performed in anasthetized 24-wk-old mice. As we previously showed (15), cardiac structural and functional parameters were not significantly different between WT and SCD1-/-mice ( Table 2 ). The ob/ob mice had a larger left ventricular (LV) diameter and significantly increased LV mass than the ob/ob;SCD1-/-, measure of LV function, was marginally different between ob/ob and ob/ob;SCD1-/-mice. On Doppler flow analysis, E/Ea ratio was reduced by 57% in ob/ob mice compared to WT, indicating a diastolic dysfunction in ob/ob mice. Although the E/Ea ratio in the heart of ob/ob;SCD1-/-mice was still significantly lower than in WT, SCD1 deficiency increased the E/Ea ratio by 27% in the heart of these mice compared to ob/ob mice ( Table 2 ).
The activity of SCD is decreased in the heart of ob/ob;SCD1-/-mice
The total activity of SCD was more then 2-fold higher in the heart of ob/ob mice compared to WT controls ( Fig. 2A ), whereas SCD1 deficiency decreased SCD activity by 58% in the hearts of double knockout ob/ob;SCD1-/-compared to ob/ob mice ( Fig. 2A ). Changes in SCD activity were coupled with the total levels of cardiac 18:1n9, 16:1n7 fatty acids (Fig. 2B ). We measured the mRNA levels of SCD1 and cardiac-specific SCD4 which are main isoforms of SCD expressed in the heart (Miyazaki 2004 ). In WT mice, mRNA level of SCD1 was about 4-fold higher then mRNA level of SCD4 (p<0.001), however, SCD4 gene expression was significantly increased in the heart of ob/ob mice ( Fig. 2C ). SCD1 deficiency decreased SCD activity without affecting SCD4 gene expression ( Fig. 2A-C ).
Decreased cardiac steatosis in ob/ob;SCD1-/-mice
To test whether improvement in left ventricle function in ob/ob;SCD1-/-mice was associated with reduction in heart steatosis we analyzed intracellular neutral lipid accumulation. The levels of free fatty acid (FFA), diacylglycerol (DAG), and TG in the heart of ob/ob;SCD1-/-were significantly reduced by 39%, 20%, and 33%, respectively, compared to ob/ob mice but comparable to values noted in WT (Fig. 3A, B ). Heart phospholipids (PL) content was similar in all studied groups (Fig. 3C ). deficiency also resulted in 23% increase in polyunsaturated FA content in PL fraction in the heart of ob/ob mice (data not shown). To address reasons of decreased heart steatosis observed in ob/ob;SCD1-/-mice, we assessed mRNA levels of peroxisome proliferator-activated receptor-γ (PPARγ), a transcription factor that contributes to increased cellular assimilation of lipids (26) .
SCD1 deficiency did not change PPARγ mRNA levels (Fig. 4A) , suggesting that PPARγ is not involved in regulation of fat content in the heart of these animals. Next we measured mRNA level of glycerol-3-phosphate acyltransferase (GPAT) and diacylglycerol acyltransferase (DGAT), which catalyze the first and the final step in TG synthesis, respectively. GPAT and DGAT mRNA levels were significantly increased in hearts of ob/ob mice, consistent with their increased lipid accumulation (Fig. 4A) . However, SCD1 deletion decreased the expression of these two genes in ob/ob mice (Fig. 4A) . FA uptake by cardiac myocytes occurs by two main transport processes: protein-mediated transport, which accounts for ~80% of total FA uptake, and by simple diffusion. Fatty acid translocase CD36 (CD36) and fatty acid transport protein (FATP) are the major proteins responsible for membrane FA transport. We measured both CD36 and FATP mRNA and protein levels by real-time PCR and Western blottiong, respectively. The mRNA and protein levels of both CD36 and FATP were significantly lower in the heart of ob/ob;SCD1-/-mice than in ob/ob controls (Fig. 4B,C) . These results suggest that lower rates of FA transport and reduced lipogenesis contribute to the decreased lipid content observed in hearts of SCD1-deficient ob/ob mice.
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Decreased cardiac FA β-oxidation in SCD1 deficient ob/ob mice
We measured oxidation of [ 14 C]palmitoyl-CoA in heart mitochondria. Palmitoyl-CoA β-oxidation was increased in the heart of ob/ob mice in comparison to WT controls, and significantly reduced in ob/ob;SCD1-/-compared to ob/ob mice (Fig. 5A ). There were no significant differences in the rate of FA oxidation between WT and ob/ob;SCD1-/-double knockout mice (Fig. 5A) . To address the possible reasons for decreased FA oxidation in the myocardium of SCD1 deficient ob/ob mice, we measured mRNA levels of PPARα, a primary nuclear factor is known to stimulate genes of lipid oxidation. mRNA levels of PPARα were increased by 25% in the hearts of ob/ob mice as compared with WT animals. Interestingly, PPARα levels were not elevated in the myocardium of ob/ob;SCD1-/-mice relative to WT mice (Fig. 5B) . We also measured expression of carnitine palmitoyltransferase 1 (CPT1) and acyl-CoA oxidase (ACO), both of which are target genes of PPARα. The levels of both CPT1 and ACO were significantly increased in ob/ob mice relative to WT mice. Interestingly, however, they were significantly reduced in the hearts of ob/ob;SCD1-/-mice relative to ob/ob mice (Fig. 5B) . These results suggest that the reduced expression of oxidative genes in the myocardium of ob/ob;SCD1-/-mice is associated with decreased FA oxidation measured in these animals.
Decreased rate of de novo synthesis of cardiac ceramide caused by SCD1 knockdown
SPT is the rate-limiting enzyme in de novo synthesis of ceramide (27) . The mRNA levels of both SPT subunits (LCB1 and LCB2) were reduced by 70% and 65%, respectively in the heart of double mutant ob/ob;SCD1-/-mice compared to ob/ob mice and were even lower than values measured in WT mice (Fig. 6A) . SPT activity was increased in the hearts of ob/ob mice by 60% when compared to WT mice and SCD1 deficiency educed the enzyme activity in the hearts of ob/ob;SCD1-/-mice to the levels measured in WT animals (Fig. 6B ). The differences in the activity of SPT in all of the experimental groups paralleled the changes in intracellular level of palmitate (Fig. 2B) , that is a preferred substrate of SPT. To determine whether SCD1 deficiency affects de novo synthesis of ceramide in the heart, we analyzed the incorporation of [ 14 C]palmitic acid into the ceramide fraction. The rate of incorporation of labeled palmitate into ceramide was decreased in the heart of ob/ob;SCD1-/-mice by 55% compared to ob/ob mice and was comparable to WT (Fig. 6C) . The total content of ceramide was increased by 62% in the heart of ob/ob mice compared to WT controls (Fig. 6D ). SCD1 deficiency decreased the ceramide content by 34% in the heart of ob/ob;SCD1-/-mice compared to ob/ob mice (Fig. 6D ).
SCD1 deficiency decreases apoptosis in the heart of ob/ob mice
Ceramide has been shown in recent years to be critically involved in cardiac apoptosis (28).
There is evidence that ceramide upregulates nitric oxide synthase (iNOS) and increases NO production, which is believed to result in apoptosis (2, 3). Another mechanism for ceramideinduced apoptosis involves down-regulation of the antiapoptotic factor Bcl-2 and activation of caspase-3 (29, 30). To test the whether SCD1 deficiency reduces the rate of ceramide-mediated apoptosis in the heart, we analyzed iNOS activity and mRNA levels of Bcl2 as well as activity of caspase-3 in our mice. We found that iNOS activity is 67% greater in the myocardium of ob/ob mice than in WT controls (Fig. 7A) , whereas SCD1 deficiency decreases iNOS activity by 37%
in the hearts of double knockout ob/ob;SCD1-/-mice, compared to ob/ob mice (Fig. 7A ). Bcl2 mRNA levels were increased by 63% in the hearts of ob/ob;SCD1-/-mice relative to ob/ob mice (Fig. 7B) . Also, activity of caspase-3, an indicator of cardiac apoptosis (31), was decreased by 33% in the heart of ob/ob;SCD1-/-double mutant mice relative to ob/ob mice, which had a significant elevation of caspase-3 activity (Fig. 7C) . Previously, we showed that SCD1 deficiency reduces accumulation of intracellular lipids in skeletal muscle and liver by downregulating lipid synthesis and increasing the rate of β-oxidation (12, 33). The present study reveals that loss of SCD1 function decreases FFA, DAG and TG levels in the heart of ob/ob mice, however, the decreased cardiac steatosis observed in ob/ob;SCD1-/-mice is not due to increased FA oxidation as evidenced by reduced rate of palmitoyl-CoA oxidation and decreased expression of CPT1 and ACO genes. In SCD1 knockout mice reduced FA β-oxidation is coupled with increased glucose oxidation in the heart (15). It is thus possible that similar changes in substrate utilization may occur also in ob/ob;SCD1-/-mice, because a decreased cardiac FA oxidation is accompanied by increased oxygen consumption in SCD1 deficient ob/ob mice (13).
To elucidate the mechanisms by which SCD1 deficiency reduces lipid content in the leptin-deficient heart, we analyzed the expression of the transcription factor PPARγ, that contributes to the cellular assimilation of lipids (26) , and has been shown to be increased in lipotoxic cardiomyopathies (8) . In the present study we did not find differences in PPARγ expression between ob/ob;SCD1-/-and ob/ob mice; however mRNA levels of GPAT and DGAT that are involved in TG synthesis, were significantly lower in the myocardium of ob/ob;SCD1-/-than in ob/ob mice. In addition, protein and mRNA levels of two membrane FA transporters, CD36 and FATP, were decreased in the heart of ob/ob;SCD1-/-mice compared to ob/ob controls.
These results together with increased plasma TG and FFA levels in ob/ob;SCD1-/-mice, suggest that lower rate of intracellular FA transport and reduced lipogenesis, rather then FA availability, are coupled to both reduced FA β-oxidation and deceased lipogenesis in ob/ob;SCD1-/-heart.
It has been proposed that excessive deposition of TG in non adipose tissues enlarges the intracellular pool of fatty acyl-CoA, thereby providing substrate for nonoxidative metabolic pathways, such as ceramide synthesis. Increased ceramide levels lead to cell dysfunction and death through apoptosis (32). Lipoapoptosis is also observed in cardiomyocytes and leads to the development of obesity-related heart failure (4). This effect was observed in obese ZDF rats which at 14 weeks of age have ceramide levels 2-to 3-fold higher than in control group.
Troglitazone therapy of obese fa/fa rats decreased TG levels, accompanied by reduced ceramide levels (4). In the present study we observed reduced TG and ceramide levels in the heart of ob/ob;SCD1-/-mice in comparison to control ob/ob mice. Notably, the ceramide level in the proposed that ceramide up-regulates iNOS expression and increases NO production, which causes an increase in peroxynitrite and apoptosis. Also downregulation of caspase-3 was often linked with ceramide action (29, 30). Ravid et al. (29) showed that ceramide-mediated apoptosis is blocked by a general caspase inhibitor, Boc-D-fluoromethylketone. Ruvolo et al. (36) established that exogenous ceramide can downregulate antiapoptotic factor Bcl-2 expression and phosphorylation, and thereby activate caspase-3 and apoptosis. It has also been suggested that the antiapoptotic effect of Bcl-2 in the heart may occur via the modulation of ceramide production, and prevention of ceramide-mediated caspase activation (37) . We found increased mRNA levels by guest, on October 14, 2017 www.jlr.org
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of Bcl-2 in the heart of ob/ob;SCD1-/-mice compared to ob/ob controls. Thus increased gene expression of Bcl-2, could be another factor contributing to the down-regulation of caspase-3 activity and reduction in apoptosis rate in the heart of ob/ob;SCD1-/-double knockout mice.
Since reduced apoptosis rate in cardiomyocytes was shown to improve cardiac function (1), the obtained results suggest that inhibition of lipid-induced apoptosis could be responsible for improved left ventricle function in ob/ob mice caused by SCD1 deficiency.
In summary, the results presented herein demonstrate the importance of SCD1 in the pathogenesis of lipotoxic heart disease. SCD1 deficiency reduced heart steatosis and the rate of cardiomyocyte apoptosis, and significantly improved systolic and diastolic function of the left ventricle in ob/ob mice. As shown schematically in Fig. 8 , the disruption of the SCD1 gene reduces FA transport and expression of lipogenic genes which leads to reductions in intracellular FFA, DAG, and TG accumulation in the heart. Decreased FA content together with reduced expression of oxidative genes results in reduction in β-oxidation rate which itself might have positive effect on the heart function (8, 32). However, SCD1 deficiency also reduces the activity and gene expression of SPT, and leads to a decrease in de novo ceramide synthesis and its accumulation. Reduced ceramide levels might be accountable for decrease in cardiac apoptosis via increase in expression of Bcl-2 and inhibition of iNOS pathway (Fig. 8) . Reduction in myocardial lipid accumulation and inhibition of lipid-induced apoptosis appear to be one of the main mechanisms responsible for improved left ventricle function in ob/ob mice due to SCD1 deficiency. Decreased myocardial lipid content and improved cardiac function are often coupled with the reduction in systemic lipid balance [4] . While SCD1 deficiency does not reduce plasma TG and FFA concentrations, it significantly decreases body weight and adiposity of ob/ob mice.
It is thus possible that the protective effects of SCD1 deletion may also be coupled to the lean Results are mean ± SD; *p<0.05 vs WT mice; #p<0.05 vs ob/ob mice; N=6. nd -not detectable. 
